Rytary (Carbidopa / Levodopa Extended-Release Capsules): Cost Across Insurances
Complete cell-by-cell comparison across Self-Pay Cash, Original Medicare, 6 Major California Commercial Payers (Anthem, Blue Shield, UnitedHealthcare, Aetna, Cigna, Kaiser Permanente), and Medi-Cal — with every cell labeled with its official data source and effective date.
Accuracy Level — Tier 1 Published Prices: You are currently viewing general published hospital cash prices, Medicare baselines, and multi-payer ranges. Add your insurance card to unlock Tier 2 plan pricing and Tier 3 verified benefit checks.
Hospital procedure cells are extracted from 14 Bay Area hospital MRFs (45 CFR § 180.50, Oct 2026); medication cells use CMS NADAC (as of 2026-10-28) & CY 2026 Medicare Part D / Medi-Cal Rx rules.
| Parkinson's Service / Medication | Self-Pay / Cash Price Hospital MRF / Retail Cash | Medicare Rate 2026 CMS / NADAC / Part D | Anthem Blue Cross MRF Negotiated / Formulary | Blue Shield of CA MRF Negotiated / Formulary | UnitedHealthcare MRF Negotiated / Formulary | Aetna MRF Negotiated / Formulary | Cigna MRF Negotiated / Formulary | Kaiser Permanente MRF Negotiated / Formulary | Medi-Cal (CA Medicaid) CA DHCS / Medi-Cal Rx |
|---|---|---|---|---|---|---|---|---|---|
MedicationNDC 64896066101 Rytary (Carbidopa / Levodopa Extended-Release Capsules) | $410 – $1,350 / 30 days (90–270 capsules depending on daily capsule count) $410 – $1,350 / 30 days (90–270 capsules depending on daily capsule count) Source: CMS NADAC 2026 & Retail Specialty Pharmacy Cash Benchmarks (Oct 2026) Date: Oct 2026 | NADAC: $357.42 – $449.68 per 90 capsules ($1,072 – $1,349 for 270 capsules/30 days) RYTARY ER 23.75-95 MG ($3.97980/EA; Generic ER $3.18395/EA) to RYTARY ER 61.25-245 MG ($4.99647/EA; Generic ER $3.94968/EA) • Medicare Part D patient cost: 25%–45% coinsurance or $47–$100 copay until reaching the $2,100 annual Part D out-of-pocket cap ($0 thereafter) Source: CMS NADAC 2026 (data.medicaid.gov Dataset fbb83258-11c7-47f5-8b18-5f8e79f7e704) & CMS CY 2026 Medicare Part D Formulary & Utilization Management File (Oct 2026) Date: 2026-10-28 | Not published Tier 3/4 with Step Therapy (must try generic carbidopa/levodopa IR & ER first). Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved. Source: Anthem Blue Cross 2026 CA Commercial Formulary & CA Health & Safety Code § 1367.241 (SB 1021) Date: Oct 2026 | Not published Tier 4 Non-Preferred / Prior Authorization required. Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved. Source: Blue Shield of CA 2026 CA Commercial Formulary & CA Health & Safety Code § 1367.241 (SB 1021) Date: Oct 2026 | Not published Tier 3/4 with Prior Authorization and Step Therapy. Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved. Source: UnitedHealthcare 2026 CA Commercial Formulary & CA Health & Safety Code § 1367.241 (SB 1021) Date: Oct 2026 | Not published Non-Preferred Brand; Prior Authorization + Step Therapy required. Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved. Source: Aetna 2026 CA Commercial Formulary & CA Health & Safety Code § 1367.241 (SB 1021) Date: Oct 2026 | Not published Tier 3/4; Prior Authorization required. Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved. Source: Cigna 2026 CA Commercial Formulary & CA Health & Safety Code § 1367.241 (SB 1021) Date: Oct 2026 | Not published Non-Formulary (requires formal formulary exception documenting failure of generic IR + ER + adjunct COMT/MAOB therapy). Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved. Source: Kaiser Permanente 2026 CA Commercial Formulary & CA Health & Safety Code § 1367.241 (SB 1021) Date: Oct 2026 | $0 patient copay $0 copay IF approved via Medi-Cal Rx Prior Authorization (requires documented failure of generic CDL carbidopa/levodopa formulations). Source: CA DHCS Medi-Cal Rx Contract Drug List (CDL) & PA Policy Date: Oct 2026 |
Every Insurance Cell for Rytary — With Source & Date Citations
Self-Pay / Discounted Cash Price
$410 – $1,350 / 30 days (90–270 capsules depending on daily capsule count)
Original Medicare (CMS 2026 / NADAC / Part D)
RYTARY ER 23.75-95 MG ($3.97980/EA; Generic ER $3.18395/EA) to RYTARY ER 61.25-245 MG ($4.99647/EA; Generic ER $3.94968/EA) • Medicare Part D patient cost: 25%–45% coinsurance or $47–$100 copay until reaching the $2,100 annual Part D out-of-pocket cap ($0 thereafter)
Anthem Blue Cross (California)
Tier 3/4 with Step Therapy (must try generic carbidopa/levodopa IR & ER first). Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved.
Blue Shield of California
Tier 4 Non-Preferred / Prior Authorization required. Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved.
UnitedHealthcare (UHC)
Tier 3/4 with Prior Authorization and Step Therapy. Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved.
Aetna
Non-Preferred Brand; Prior Authorization + Step Therapy required. Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved.
Cigna
Tier 3/4; Prior Authorization required. Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved.
Kaiser Permanente (Northern CA)
Non-Formulary (requires formal formulary exception documenting failure of generic IR + ER + adjunct COMT/MAOB therapy). Commercial insurer-PBM net negotiated drug price is proprietary; CA SB 1021 caps state-regulated commercial copay at ≤ $250/30d if PA is approved.
Medi-Cal (California Medicaid / Medi-Cal Rx)
$0 copay IF approved via Medi-Cal Rx Prior Authorization (requires documented failure of generic CDL carbidopa/levodopa formulations).
Rytary (Carbidopa / Levodopa Extended-Release Capsules) — Clinical & Formulary Summary
What it's for: Extended-release capsule combining immediate- and delayed-release carbidopa/levodopa beads to reduce daily 'OFF' time in patients with motor fluctuations. (Source: FDA Prescribing Information (NDA 203312) & Parkinson's Foundation Medications Guide)